|1.||Wu, Jen-Leih: 2 articles (05/2015 - 04/2015)|
|2.||Chen, Jyh-Yih: 2 articles (05/2015 - 04/2015)|
|3.||Hui, Cho-Fat: 2 articles (05/2015 - 04/2015)|
|4.||Maynard, Greg: 2 articles (04/2015 - 01/2009)|
|5.||Fink, Ed: 2 articles (04/2015 - 01/2009)|
|6.||Renvall, Marian: 2 articles (04/2015 - 01/2009)|
|7.||Setzer, Frank C: 2 articles (02/2012 - 09/2011)|
|8.||An, Hongyu: 2 articles (01/2011 - 02/2003)|
|9.||Lee, Jin-Moo: 2 articles (01/2011 - 02/2003)|
|10.||Lin, Weili: 2 articles (01/2011 - 02/2003)|
|1.||Dysphonia (Spastic Dysphonia)
|2.||Osteosarcoma (Osteogenic Sarcoma)
08/01/2000 - "Cells in suspension were added to various activity concentrations of the anti-osteosarcoma monoclonal antibody TP-3 radiolabelled with 211At. "
04/01/1998 - "The radioisotope was conjugated to either the osteosarcoma-specific monoclonal antibody TP-3 or the non-specific polyclonal antibody hlgGkappa. "
09/01/1994 - "Four dogs with histologically confirmed osteogenic sarcoma were studied with PET following intravenous injection of the 18F-labeled Fab fragment of TP-3, a monoclonal antibody specific for human and canine osteosarcomas. "
10/01/1998 - "The monoclonal antibody (mAb) TP-3 binds selectively to human and canine osteosarcoma (OS) cells and is therefore a potential candidate for use as a targeting agent in radioimmunoimaging and therapy of OS metastases. "
01/01/2005 - "Compared with the monovalent TP-3 immunotoxin, the bivalent TP-3 immunotoxin showed an approximately sevenfold increase in cytotoxic activity against three osteosarcoma cell lines which react with the TP-3 monoclonal antibody. "
09/01/2011 - "Twenty patients were selected, and two teeth of each participant (n = 40) were analyzed, regardless of the quadrant and the area irradiated, at four different time points: TP1, before RT; TP2, at the beginning of RT with radiation doses between 30 and 35 Gy; TP3, at the end of RT with radiation doses between 60 and 70 Gy; and TP4, 4 to 5 months after the beginning of cancer treatment. "
09/01/2000 - "Control injections did not affect the tumor/blood ratio, but increased the uptake of 125I-labeled TP-3 significantly in kidney and spleen (p < 0.05). "
09/01/2000 - "BTH injections increased the tumor uptake of specific 125I-labeled TP-3 significantly by approximately 70% in mice receiving 3 fractions compared to 1-2 fractions of the antibody (p < 0.05). "
01/01/2005 - "The dose at which the bivalent TP-3 immunotoxin produces complete regressions of tumors is (1/2) that of the monovalent TP-3 immunotoxin. "
09/01/2000 - "The tumor/normal tissue ratio in mice receiving 3 fractions of 125I-labeled TP-3 (n = 5) was significantly higher for all tissues, compared with mice receiving 1-2 fractions (n = 4) (p < 0.05). "
04/01/2015 - "Administration of TP3 (150 μg/mouse) or TP4 (50 μg/mouse) 30 min after infection with K. "
07/01/2001 - "A more detailed investigation of the infection was performed for the mutants T1026, TP3 and G31, differing in their host shutoff effects related to M protein. "
05/30/2015 - "TP3 treatment increased survival by 100% at 8 days after infection, and accelerated the progression of proliferation, remodeling, and maturation of infected wounds. "
05/30/2015 - "Use of tilapia piscidin 3 (TP3) to protect against MRSA infection in mice with skin injuries."
|8.||Immunoglobulin G (IgG)
|9.||DNA (Deoxyribonucleic Acid)
|3.||Heterologous Transplantation (Xenotransplantation)